Glenmark Pharmaceuticals Ltd
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 |
|---|---|---|---|
| Revenue | 2,584.01 | 2,773.40 | 2,454.45 |
| Operating Expense | 1,936.95 | 1,821.74 | 2,483.80 |
| Net Profit | 434.89 | 735.64 | -73.90 |
| Net Profit Margin | 16.83% | 26.52% | -3.01% |
| Earning Per Share | 15.41 | 26.07 | -2.62 |
| EBIDTA | 632.57 | 934.05 | 4.14 |
| Effective Tax Rate | 16.03% | 11.86% | -0% |
Particulars
Sep 2026
Revenue2,584.01
Operating Expense1,936.95
Net Profit434.89
Net Profit Margin16.83
Earning Per Share15.41
EBIDTA632.57
Effective Tax Rate16.03
